Previous studies provided robust evidence of the antitumor activity of liraglutide, a long-acting GLP-1 analogue, in which liraglutide was shown to significantly reduce both the tumorigenicity and metastatic spread of human pancreatic cancer cells [40]. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.